Bristol-Myers Squibb (BMY) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
February 5, 2018 6:59 AM ESTIncreases Fourth Quarter Revenues 4% to $5.4 Billion, 7% for Full Year to $20.8 Billion Posts Fourth Quarter GAAP Loss Per Share of $1.42, Driven by Tax Reform Charges, Non-GAAP EPS of $0.68 Achieves Important Clinical and Regulatory Milestones in Oncology Opdivo Plus Yervoy Demonstrates Superior Progression-Free Survival vs. Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients with High Tumor Mutation Burden in CheckMate -227 Opdivo Approved in the U.S. for Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease... More
